Skip to content

Effectiveness of dextrose injection for relief of pain and stiffness of shoulder joint

The efficacy of dextrose prolotherapy for adhesive capsulitis of shoulder: A randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009581
Enrollment
30
Registered
2017-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- adhesive capsulitis of shoulder Health Condition 2: M750- Adhesive capsulitis of shoulder

Interventions

Intervention1: Dextrose Prolotherapy Group A: mixture of 5.0 ml of 25% dextrose and 1.0 ml 2% lignocaine Control Intervention1: Sham Prolotherapy Group B: A mixture of 1 ml of normal saline and 1.0 ml

Sponsors

All India Institute of Medical Sciences New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Limitation of passive movement in the glenohumeral joint compared with the unaffected side, more than 30 degrees for at least two of these two movements: abduction or external rotation 2. Pain in predominantly one shoulder lasting for more than 3 months, less than 2 years. 3. Patients who are willing to come for follow up

Exclusion criteria

Exclusion criteria: 1. Less than 35yrs of age. 2. Pain in the shoulder joint less than 3 months duration. 3. Any previous injection in the affected shoulder 4. Shoulder pain due to acute trauma fractures, bony deformity, glenohumeral joint arthritis, acromioclavicular joint pathology and rotator cuff disorder, cervical rediculopathy 5. Bleeding disorder, acute and chronic infection, allergy to local anesthetic or any other contraindication for injection. 6. Uncontrolled diabetes mellitus 7. Pregnancy

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale (VAS) Shoulder pain and disability index (SPADI) Passive range of motion of affected shoulderTimepoint: At Base line At 8 week At 12 week

Secondary

MeasureTime frame
No secondary outcomeTimepoint: not applicable

Countries

India

Contacts

Public ContactOSAMA NEYAZ

All India Institute of Medical Sciences, New Delhi

osamaneyaz@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026